Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | GNRHR | P30968 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | PPIA | P62937 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7939474 | 0.74 | TAAR1 (0.38) | NOS3TAAR1KDM1AKDM1BHTR2B | |
| SCHEMBL14095078 | 0.66 | NPC1 (0.30) | NPC1RAB9A | |
| SCHEMBL8974385 | 0.62 | CYP2A6 (0.50) | TAAR1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL38651812 | 0.62 | NOS3 (0.48) | NOS3NOS2KDM1AKDM1BRXFP1 | |
| SCHEMBL9627687 | 0.61 | TAAR1 (0.62) | TAAR1DPP4 | |
| SCHEMBL13844319 | 0.61 | DRD2 (0.39) | TAAR1HTR2BMEN1NPC1RAB9A | |
| SCHEMBL14457892 | 0.60 | KDM4E (0.38) | NOS3DPP4 | |
| SCHEMBL8063260 | 0.60 | NOS3 (1.00) | NOS3NOS2KDM1AKDM1B | |
| SCHEMBL3619290 | 0.60 | TAAR1 (0.72) | TAAR1 | |
| SCHEMBL3619289 | 0.60 | TAAR1 (0.72) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266765-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6740656-B2 | GNRH RECEPTOR ANTAGONISTS ARE DISCLOSED WHICH HAVE UTILITY IN THE TREATMENT OF A VARIETY OF SEX-HORMONE RELATED CONDITIONS IN BOTH MEN AND WOMEN. THE COMPOUNDS OF THIS INVENTION HAVE THE STRUCTURE:PRODRUGS, STEREOISOMERS AND DRUGS | NEUROCRINE BIOSCIENCES, INC. | 2004-05-25 | — | — | US | disclosed |
| EP-1412363-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | Neurocrine Biosciences, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030109535-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2003-06-12 | — | — | US | disclosed |
| WO-2003011870-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266765-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | NOS3 1025/4885NOS2 2476/4885TAAR1 563/4885 |
| US-20030109535-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | NOS3 1025/4885NOS2 2476/4885TAAR1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.